Market's view on Arecor Therape
Published on April 2024
- Stock watchers indicate a competitive scenario for the company as they aim to develop an oral weight loss drug that reduces the amount of active drug needed, amidst significant industry interest.
- Previous trial results of AT278 significantly influenced the company’s share price, and investors await the forthcoming results.
- The company’s shares experienced a substantial spike post-IPO, followed by a steady decline over 2.5 years, raising questions about investment timing and decisions.
- The recurring issue on the AIM market is highlighted where companies face cash shortages, leading to a cycle of share price declines and insufficient fundraising.
- Stock watchers note an encouraging update which could potentially affect the market presence of the company’s shares.
- Arecor’s partnership with Sanofi on INBRX-101, an asset showing commercial promise, is noted alongside discussions about the financial implications of royalty arrangements.
- Discussions about the potential financial impact of the INBRX-101 deal with Sanofi and the value attributed to Arecor based on its royalty agreement.
- Arecor’s development of a proprietary ready-to-dilute oncology product could significantly benefit current treatment practices by simplifying administration and reducing patient treatment time.